What is anti CD47?

What is anti CD47?

A monoclonal antibody targeting the human cell surface antigen CD47, with potential phagocytosis-inducing and antineoplastic activities.

Do macrophages express CD47?

Macrophages are a key cell type in the innate immune response with CD47 being identified as a dominant macrophage checkpoint. CD47 is a “do not eat me” signal, overexpressed in myeloid malignancies that leads to tumor evasion of phagocytosis by macrophages.

What is CD47 used for?

Similarly, CD47 has been found playing important roles in hematological malignancies, including in non-Hodgkin lymphomas (NHL), lymphoblastic lymphoma/acute lymphoblastic leukemia (LBL/ALL), acute myeloid leukemia (AML) and multiple myeloma (MM) [5, 6].

What are CD47 cells?

CD47 is a kind of protein that is found on the surface of many cells in the body. It tells circulating immune cells called macrophages not to eat these cells. The body uses the CD47 protein to protect cells that should be protected and to help dispose of cells that are aged or diseased.

Is Magrolimab FDA approved?

Magrolimab is an investigational product and is not approved by any regulatory authority for any use; its safety and efficacy have not been established.

What is Hu5F9 G4?

Background. The Hu5F9-G4 (hereafter, 5F9) antibody is a macrophage immune checkpoint inhibitor blocking CD47 that induces tumor-cell phagocytosis. 5F9 synergizes with rituximab to eliminate B-cell non-Hodgkin’s lymphoma cells by enhancing macrophage-mediated antibody-dependent cellular phagocytosis.

What cells are CD47 expressed?

CD47 is expressed on the surface of non-malignant cells as well as multiple types of cancer cells and can bind to the SIRPα transmembrane protein on myeloid cells (especially macrophages) to form the CD47-SIRPα signaling complex (23).

How is Magrolimab administered?

In cycle 3 and thereafter, magrolimab will be given at 30 mg/kg every 2 weeks on days 1 and 15. Those on the control arm were given placebo to match magrolimab. Azacitidine was administered in both arms at a dose of 75 mg/m2 on days 1 to 7, or days 1 to 5 and 8 to 9 of each treatment cycle.

What TTI 621?

TTI-621 (SIRPα-IgG1 Fc) is a novel checkpoint inhibitor that activates antitumor activity by blocking the CD47 “don’t eat me” signal. This first-in-human phase I study (NCT02663518) evaluated the safety and activity of TTI-621 in relapsed/refractory (R/R) hematologic malignancies.

What is CD47 a marker for?

The immune system recognizes invaders as foreign because they express determinants that are absent on host cells or because they lack “markers of self” that are normally present. Here we show that CD47 (integrin-associated protein) functions as a marker of self on murine red blood cells.

What is the cost of azacitidine?

Costs

Is azacitidine a chemotherapy?

Drug Type: Azacitadine is a cytotoxic chemotherapy drug. This medication is classified as an antimetobolite and a demethylating agent (for more detail, see “How Azacitadine Works” below).

How long is a cycle of azacitidine?

You usually have azacitidine as a course of several cycles of treatment. You have treatment each day for a week and then 3 weeks with no treatment. This makes up a treatment cycle. You usually have at least 6 cycles and the treatment continues for as long as it is working.

What are the side effects of azacitidine?

Azacitidine may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:

• nausea.
• vomiting.
• diarrhea.
• constipation.
• sores on the mouth or tongue.
• hemorrhoids.
• stomach pain or tenderness.
• heartburn.

Can azacitidine cure AML?

Abstract. Azacitidine is recommended front-line treatment for older patients with acute myeloid leukemia (AML) who are not candidates for intensive treatment regimens, and was recently granted approval in the European Union for treatment of adult AML.